UB Paderborn / Katalog / Suche / in CDI

WHO's Attempt to Navigate Commercial Influence and Conflicts of Interest in Nutrition Programs While Engaging With Non-State Actors: Reflections on WHO Guidance for Nation States Comment on "Towards Preventing and Managing Conflict of Interest in Nutrition Policy? An Analysis of Submissions to a Consultation on a Draft WHO Tool"

International journal of health policy and management, 2022-03, Vol.11 (3), p.386-390

Rodwin, Marc A

2022

Volltextzugriff (PDF)

Assessing US Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies

Journal of health politics, policy and law, 2022-12, Vol.47 (6), p.755-778

Rodwin, Marc A.

2022

Volltextzugriff (PDF)

Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States

International journal of health services, 2021-07, Vol.51 (3), p.379-391

Rodwin, Marc A.

2021

Volltextzugriff (PDF)

Pharmaceutical Price and Spending Controls in France: Lessons for the United States

International journal of health services, 2020-04, Vol.50 (2), p.156-165

Rodwin, Marc A.

2020

Volltextzugriff (PDF)

Pathways to independence: towards producing and using trustworthy evidence

BMJ (Online), 2019-12, Vol.367, p.l6576

2019

Volltextzugriff (PDF)

Attempts to redefine conflicts of interest

Accountability in research, 2018-01, Vol.25 (2), p.67-78

Rodwin, Marc A.

2018

Volltextzugriff (PDF)

German Pharmaceutical Pricing: Lessons for the United States

International journal of health services, 2022-01, Vol.52 (1), p.146-158

2022

Volltextzugriff (PDF)

Conflicts of Interest in Human Subject Research: The Insufficiency of U.S. and International Standards

American journal of law & medicine, 2019-12, Vol.45 (4), p.303-330

Rodwin, Marc A.

2019

Volltextzugriff (PDF)

Corrigendum to “The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017” [Eur J Canc 145 (2021) 11–18]

European journal of cancer (1990), 2021-07, Vol.152, p.259-261

2021

Volltextzugriff (PDF)

Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform

The Journal of law, medicine & ethics, 2012-09, Vol.40 (3), p.511-522

Rodwin, Marc A.

2012

Volltextzugriff (PDF)

Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use

The Journal of law, medicine & ethics, 2013-09, Vol.41 (3), p.654-664

Rodwin, Marc A.

2013

Volltextzugriff (PDF)

The No Surprises Act: A Conservative Band-Aid to Protect Business as Usual

International Journal of Social Determinants of Health and Health Services, 2023-01, Vol.53 (1), p.63-68

2023

Volltextzugriff (PDF)

The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017

European journal of cancer (1990), 2021-03, Vol.145, p.11-18

2021

Volltextzugriff (PDF)

The case for public ownership of patient data

JAMA : the journal of the American Medical Association, 2009-07, Vol.302 (1), p.86

Rodwin, Marc A

2009

Volltextzugriff (PDF)

Clinical trial data as a public good

JAMA : the journal of the American Medical Association, 2012-09, Vol.308 (9), p.871

2012

Volltextzugriff (PDF)

INTRODUCTION: Institutional Corruption and the Pharmaceutical Policy

The Journal of law, medicine & ethics, 2013-09, Vol.41 (3), p.544-552

Rodwin, Marc A.

2013

Volltextzugriff (PDF)

Five Un-Easy Pieces of Pharmaceutical Policy Reform

The Journal of law, medicine & ethics, 2013-09, Vol.41 (3), p.581-589

Rodwin, Marc A.

2013

Volltextzugriff (PDF)

Patient Data: Property, Privacy & the Public Interest

American journal of law & medicine, 2010-12, Vol.36 (4), p.586-618

Rodwin, Marc A.

2010

Volltextzugriff (PDF)

Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons from the United States, France, and Japan

The Journal of law, medicine & ethics, 2011-12, Vol.39 (4), p.662-670

Rodwin, Marc A.

2011

Volltextzugriff (PDF)

Drug Advertising, Continuing Medical Education, and Physician Prescribing: A Historical Review and Reform Proposal

The Journal of law, medicine & ethics, 2010-12, Vol.38 (4), p.807-815

Rodwin, Marc A.

2010

Volltextzugriff (PDF)

Do We Need Stronger Sanctions to Ensure Legal Compliance By Pharmaceutical Firms?

Food and drug law journal, 2015-01, Vol.70 (3), p.435-452

Rodwin, Marc A.

2015

Volltextzugriff (PDF)

New standards for medical review organizations: holding them and health plans accountable for their decisions

Health affairs (Millwood, Va.), 2011-03, Vol.30 (3), p.519-524

Rodwin, Marc A

2011

Volltextzugriff (PDF)

Institutional Corruption and the Pharmaceutical Policy

The Journal of law, medicine & ethics, 2013-10, Vol.41 (3), p.544-552

Rodwin, Marc A.

2013

Volltextzugriff (PDF)

Why We Need Health Care Reform Now

Journal of health politics, policy and law, 2011-06, Vol.36 (3), p.597-601

Rodwin, Marc A.

2011

Volltextzugriff (PDF)

Financial incentives for doctors

BMJ (Online), 2004-06, Vol.328 (7452), p.1328

Rodwin, Marc A

International edition, 2004

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Assessing US Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies

Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States

Pharmaceutical Price and Spending Controls in France: Lessons for the United States

Pathways to independence: towards producing and using trustworthy evidence

Attempts to redefine conflicts of interest

German Pharmaceutical Pricing: Lessons for the United States

Conflicts of Interest in Human Subject Research: The Insufficiency of U.S. and International Standards

Corrigendum to “The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017” [Eur J Canc 145 (2021) 11–18]

Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform

Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use

The No Surprises Act: A Conservative Band-Aid to Protect Business as Usual

The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017

The case for public ownership of patient data

Clinical trial data as a public good

INTRODUCTION: Institutional Corruption and the Pharmaceutical Policy

Five Un-Easy Pieces of Pharmaceutical Policy Reform

Patient Data: Property, Privacy & the Public Interest

Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons from the United States, France, and Japan

Drug Advertising, Continuing Medical Education, and Physician Prescribing: A Historical Review and Reform Proposal

Do We Need Stronger Sanctions to Ensure Legal Compliance By Pharmaceutical Firms?

New standards for medical review organizations: holding them and health plans accountable for their decisions

Institutional Corruption and the Pharmaceutical Policy

Why We Need Health Care Reform Now

Financial incentives for doctors

Suchergebnisse filtern